Biogen, Inc. underscored its commitment to Alzheimer’s disease while announcing the discontinuation of three clinical-stage development programs as new CEO Christopher Viehbacher continues to piece together a business strategy that will return the company to steady growth beginning in 2025. Executives updated investors on Biogen’s ongoing business review during its first quarter sales and earnings call on 25 April.
Biogen’s Pipeline: Alzheimer’s Is In, Stroke Is Out
The company is prioritizing investment in the launches of Leqembi, zuranolone and newly approved Qalsody as well as key pipeline assets, while discontinuing investment in two stroke programs.
More from New Products
More from Scrip
Recent moves in the industry include C-suite changes at 23andMe, Biomea Fusion & Alector, plus Bicycle Therapeutics acquires chief medical officer from ImmunoGen.
• By
Menarini's Asia-Pacific CEO talks to Scrip about how the Italian group is tailoring its portfolio and pricing approach to local markets making strong strides in primary care and consumer health, while also charting a distinct path in rare diseases and oncology. The China market is also a key focus including as a potential source of innovation as is partnering, where the group has a rich history.
• By
Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.